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RNA sequencing of blood in coronary
artery disease: involvement of regulatory T cell
imbalance
Timothy A. McCaffrey1,4,6,10* , Ian Toma1,7,10, Zhaoquing Yang1, Richard Katz2, Jonathan Reiner2,
Ramesh Mazhari2, Palak Shah9, Michael Tackett3, Dan Jones3, Tisha Jepson3,4,10, Zachary Falk1,
Richard Wargodsky1, Dmitry Shtakalo8, Denis Antonets8, Justin Ertle1, Ju H. Kim2, Yinglei Lai5, Zeynep Arslan1,
Emily Aledort1, Maha Alfaraidy1 and Georges St. Laurent III4

Abstract
Background: Cardiovascular disease had a global prevalence of 523 million cases and 18.6 million deaths in 2019.
The current standard for diagnosing coronary artery disease (CAD) is coronary angiography. Surprisingly, despite
well-established clinical indications, up to 40% of the one million invasive cardiac catheterizations return a result of
‘no blockage’. The present studies employed RNA sequencing of whole blood to identify an RNA signature in patients
with angiographically confirmed CAD.
Methods: Whole blood RNA was depleted of ribosomal RNA (rRNA) and analyzed by single-molecule sequencing of
RNA (RNAseq) to identify transcripts associated with CAD (TRACs) in a discovery group of 96 patients presenting for
elective coronary catheterization. The resulting transcript counts were compared between groups to identify differentially expressed genes (DEGs).
Results: Surprisingly, 98% of DEGs/TRACs were down-regulated ~ 1.7-fold in patients with mild to severe CAD (> 20%
stenosis). The TRACs were independent of comorbid risk factors for CAD, such as sex, hypertension, and smoking.
Bioinformatic analysis identified an enrichment in transcripts such as FoxP1, ICOSLG, IKZF4/Eos, SMYD3, TRIM28, and
TCF3/E2A that are likely markers of regulatory T cells (Treg), consistent with known reductions in Tregs in CAD. A
validation cohort of 80 patients confirmed the overall pattern (92% down-regulation) and supported many of the
Treg-related changes. TRACs were enriched for transcripts associated with stress granules, which sequester RNAs, and
ciliary and synaptic transcripts, possibly consistent with changes in the immune synapse of developing T cells.
Conclusions: These studies identify a novel mRNA signature of a Treg-like defect in CAD patients and provides a
blueprint for a diagnostic test for CAD. The pattern of changes is consistent with stress-related changes in the maturation of T and Treg cells, possibly due to changes in the immune synapse.
Keywords: Atherosclerosis, Transcriptome, RNA sequencing, Regulatory T cells, Treg, FoxP1, FoxP3, Biomarker,
Coronary artery disease, Stress granules, Cilia, Immune synapse
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Background
There are more than a million heart attacks each year,
and 2200 Americans die of cardiovascular disease each
day, about one person every 40 s [1]. Outward symptoms of coronary artery disease (CAD) are chest pain,
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typically radiating down the left arm, and shortness of
breath upon exertion. However, chest pain and dyspnea alone are not particularly specific warning signs. In
a prospective analysis of patients presenting with chest
pain, ultimately, many cases were determined to be musculoskeletal (20%) or gastroesophageal reflux disease
(GERD) (13%), while CAD was diagnosed in only 11%
of cases, and the remaining cases were either pulmonary
[2], neurological, or idiopathic [3]. The Framingham risk
factors of advanced age, male sex, elevated cholesterol,
smoking, and hypertension, are good predictors of long
term risk (30 yr. risk, C statistic = 0.803) [4], but they are
far less accurate in acute clinical settings at determining
whether a person has CAD or not (C statistic = 0.667,
where 0.5 is random chance) [5]. Thus, there is a tremendous need for improvement in the diagnosis of CAD.
From the more than one million cardiac catheterizations yearly, 622,000 result in interventions such as stent
placement [6]. Despite the presence of CAD symptoms
and other clinical tests suggestive of CAD, 20–40%
of angiograms do not detect any occluded arteries [5,
7–10]. The American College of Cardiology’s Registry,
covering 398,978 patients, identified 39.2% of patients
undergoing invasive coronary angiography (ICA) as having less than 20% stenosis [5]. Thus, reliable blood-based
biomarkers of CAD would have the potential to reduce
the number of cardiac catheterizations on relatively low
risk individuals.
Several prior microarray studies suggested that there
is an RNA signature in blood associated with CAD
[11–15]. However, the agreement between these studies on exactly which transcripts are modulated is quite
low. Such discrepancies could have several explanations,
but likely arise from cross-hybridization noise created by
highly abundant signals, such as globins, which can overwhelm true signals in microarrays [16], and likely mask
changes of low magnitude, or larger changes in a small
subset of cells. Thus, the present studies employed
a more advanced, single-molecule RNA sequencing
(RNAseq) methodology to identify diagnostic transcripts associated with CAD (TRACs). Using RNAseq
of whole blood RNA, a novel pattern of gene expression
changes was identified that is associated with the presence of CAD, but essentially unrelated to other known
risks for CAD. This subset of TRACs is consistent with
extensive accumulating evidence for a role of regulatory
T cell (Treg) dysfunction as an important component in
the etiology of CAD.

Methods
Experimental design

The studies take advantage of the fact that up to 40%
of patients that undergo invasive coronary angiography
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(ICA) actually do not have meaningful coronary blockage. The TRACs were identified by comparing the
mRNA expression pattern of patients with CAD versus those without CAD. The strength of this model is
that blood was taken prior to the catheterization, and
the outcome of the angiography becomes known within
hours, which provides an ideal learning environment
for designing a transcriptome-based test. After the
coronary angiograms were digitally interpreted by an
attending physician, the patients were divided into 3
groups, ≤ 20% stenosis (LOW CAD), > 20% but < 70%
stenosis of any vessel (MID CAD), and ≥ 70% stenosis of any artery (CAD). For power and simplicity, initial analyses compared LOW CAD (< 20% stenosis) to
MID+ (> 20% stenosis).
Patients
Discovery cohort

Patients presenting for non-emergent complaints of typical or atypical chest pain, exertional dyspnea, or other
symptoms suggestive of CAD provided written, informed
consent for participation in this study under a protocol
approved by the George Washington University IRB.
Patients with heart failure, non-ST segment elevation MI,
and ST segment elevation MI (STEMI) were excluded
from the study. The design of the study is shown schematically in Fig. 1. Patients admitted for cardiac catheterization had three Tempus blood RNA tubes collected
by peripheral venipuncture or an indwelling catheter.
After blood sampling, these studies were purely observational and did not alter in any way the patient’s clinical
course. All relevant clinical data, including a complete
blood count (CBC), was captured for comparison to the
transcriptomic studies. From an initial enrollment of
113 patients, 96 patients had complete clinical and RNA
sequencing data for further analysis.
Validation cohort

An independent group of patients were consented at
INOVA Fairfax Hospital (Fairfax, Virginia) who were
likewise undergoing routine, elective ICA for evaluation
of suspected CAD. A total of 80 patients had sufficiently
complete clinical and RNAseq data for further analysis.
Clinical prediction model

Prior to ICA in the Discovery cohort, cardiac medical histories were examined by their attending cardiologists to determine CAD risk factors, as defined by
the 2013 ACC/AHA Guidelines on the Assessment of
Cardiovascular Risk [17]. Hypertension was defined as
a history of untreated blood pressure ≥ 140/90 mmHg
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RNA Isolation Kit (ThermoFisher Scientific) according to
the manufacturer’s protocol. After rigorous in-solution
treatment with 4 Units of DNAse (Turbo DNA-free Kit,
Ambion), the typical nucleic acid yield from 2.5 ml Tempus blood tubes averaged ~ 5 µg, with an RNA integrity
(RIN) score > 8 (10 is maximal) on Agilent 2100 Bioanalyzer. A fixed amount (4.5 ug) of the DNAsed total RNA
was depleted of ribosomal RNA (rRNA) by Ribo-Zero
rRNA Removal Kit (Illumina), then concentrated with an
RNeasy MinElute column (Qiagen), resulting in ~ 500 ng
RNA for sequencing.
Fig. 1 Schematic of study design. Patients presenting for elective
invasive coronary angiography (ICA) due to suspicion of CAD were
consented to determine whether RNA transcripts in blood could
serve as biomarkers for CAD. Typically, patients reported chest pain
or shortness of breath upon exertion. The results of the angiogram
divided the patients into groups with little to no coronary blockage
(< 20%, LOW CAD), or patients in which coronary blockage was
detected (> 20%, MID+ CAD). The blood from the patients was
frozen in Tempus blood RNA preservative, thawed, extracted for
RNA, depleted of residual genomic DNA and ribosomal RNA, and
genome-wide RNA transcript counting was performed by RNAseq.
The two groups were compared to identify transcripts unique to the
CAD patients. Images were created by the authors

and/or treatment with anti-hypertensive medications. Diabetes mellitus was defined by fasting glucose
of ≥ 126 mg/dl and/or use of insulin or oral hypoglycemic agents. Dyslipidemia was defined according to
National Cholesterol Education Program Adult Treatment Panel III guidelines or by treatment with lipid
lowering medication. Current smoking status was
defined by active smoking within 3 months of presentation. A family history of CAD was defined as MI or
cardiac death in a first-degree relative.
Chest pain was classified according to standard criteria for angina pectoris as described [18]. Typical angina
includes substernal, jaw, and/or arm pain upon exertion,
and which resolves within 15 min of rest and/or use of
nitroglycerin. Atypical angina involves 2 of these symptoms, and patients with non-cardiac chest pain experienced 1 or none of these symptoms. Dyspneic patients
were classified as having symptoms of a typical angina.
From these clinical parameters, risk points were accumulated based on age, sex, hypertension, diabetes, symptom type, family history, and smoking status, and then
compared to an ordinal risk model to predict likelihood
of CAD [18].
Transcriptome profiling
RNA processing

RNA was purified from Tempus stabilized frozen
(− 80 °C) peripheral blood samples using Tempus Spin

RNA sequencing

For RNAseq, 100 ng of rRNA-depleted RNA was fragmented and analyzed on a Heliscope true single molecule sequencer (tSMS, SeqLL, Inc.). The raw reads,
typically 40 million at 38 bp average length, were then
computationally aligned to the human genome using the
Helisphere indexDPgenomic aligner [19]. The number
of reads that align to each transcript was counted and
then corrected for transcript length and differences in
total reads obtained per patient. The raw read count was
adjusted by the size of the transcript so that long transcripts do not appear more highly expressed than short
transcripts, and by the number of total reads per sample
to produce “Reads Per Kilobase of transcript, per Million mapped” (RPKM) counts. Thus, RPKM corrects
the expression level between samples that have different
absolute numbers of reads. RPKM levels were imported
into GeneSpring GX14 suite, without additional normalization, to identify transcripts that differ between CAD
groups (TRACs). Differentially expressed genes (DEGs)
were identified by filtering low expression genes, and
then applying a combined p-value/fold change thresholds
using a Volcano plot, and Analysis of Variance (ANOV)
in Genespring.
Comparison of blood RNA preservation/isolation methods
by droplet digital PCR (ddPCR)

To determine whether TRACs were affected by the type
of blood RNA preservation method, three Tempus and
three Paxgene tubes were drawn from the same subjects
at the same time. The samples were isolated according
to manufacturer’s protocols, with the exception that the
Paxgene samples were not DNAsed on column, instead
using the Turbo DNA-free kits (Ambion) on total RNA
as a separate step, so as to be comparable with RNA isolated from Tempus tubes. After DNAse, the samples were
repurified with RNeasy MinElute kit (Qiagen) and cDNA
was reverse transcribed from 500 ng of RNA using the
iScript cDNA synthesis kit (Bio-Rad). The synthesized
cDNA was diluted 15× to 7 ng/µl and 5 µl per reaction were used in ddPCR combined with 15 µl QX200
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EvaGreen ddPCR Supermix (Bio-Rad) containing 1 µl of
2.5 pmol primers diluted from the original stock of 100
uM (pmol/uL). The ddPCR droplets were generated with
Automated Droplet Generator and signals were amplified
using the standard ddPCR protocols on a C100 Thermal
Cycler (Bio-Rad).
The Paxgene versus Tempus cDNAs were then analyzed with a set of ‘invariant’ PCR targets (beta-actin
(ACTB) and alpha-tubulin (TBA1)), selected TRACs
(DGKA, DLG1, ICOSLG, IKZF4, SMYD3, TCF3,
TRIM28), and selected targets unrelated to TRACs
(DEFA3, SELL, SOD2, IL12A). The abundance of each
transcript was expressed as a ratio of the copies/20 µl per
target in Tempus vs Paxgene samples (n = 4 samples from
3 subjects).

Results
Clinical parameters
Discovery cohort

From a total of 112 patients enrolled, 96 patients had
sufficient RNA quantity and quality, and adequate RNA
read depth for further analysis. The clinical parameters
of those 96 patients were generally comparable between
the LOW and MID+ CAD groups. After correction for
multiple testing, there were no significant differences
correlated with age, ethnicity, sex, BMI, current smoking, hypertension, dyslipidemia, diabetes, or aspirin use
(Table 1). However, there was a trend for the group of
LOW CAD patients to be somewhat younger (57.5 yr
LOW vs 62.5 yr MID+), and with fewer males (43.8%
male LOW vs 56.2% male MID+). To consider any possible confounding variables, we performed separate
comparative analysis of all major clinical parameters as
regulators of transcript profiles in blood against selected
TRACs.
Validation cohort

Patients were recruited from an ongoing cohort examining the relationship between DNA variations and CAD. A
total of 80 patients had acceptable RNAseq data for further analysis. This suburban Virginia cohort had somewhat different demographics, with mainly the minority
composition dropping from more than 50% in Discovery
group to less than 20% in the validation group, as shown
in Table 2.
Analytical parameters

The yield of RNA and the number of reads per patient
did not vary significantly, when multiple testing was
considered (Table 1). Of the 112 samples submitted for
sequencing, 16 were excluded due to low yield from RNA
purification or ribosomal depletion, inefficient cDNA
synthesis, or low yield of usable reads from RNAseq.
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There was a trend that was not statistically significant
when corrected for multiple testing that the LOW CAD
patients had slightly higher RNA yield (6.09 µg/tube
LOW, vs. 4.82 µg/tube MID + CAD, p = 0.07 uncorrected) and higher read depth (p = 0.02 uncorrected) on
RNAseq. Thus, these were considered as possible confounds in subsequent analysis.
Sources of variation in RNA yield

Patient blood samples collected with either Paxgene or
Tempus RNA preservation tubes show a surprisingly
large variation in the RNA yield, with Tempus generally
producing higher total RNA yield [20]. The total nucleic
acid yield from Tempus-preserved samples ranged
from 0.6 to 35.0 µg/tube whole blood, with a mean of
10.6 µg per tube of blood, with post-DNAse and MinElute cleanup yield of ~ 5 µg RNA per tube (Table 1).
The correlations between total nucleic acid yield and
any single blood cell count parameter were quite weak,
with only a modest correlation to absolute lymphocyte
count (r = 0.55 with N = 112, R2 = 0.31) (Additional file 1:
Fig. S1). While one outlier with a lymphocyte count of
12 K/µl yielding 35 µg of RNA seems to drive this correlation, the correlation remains modestly positive even
when that patient is omitted (r = 0.45 w/o). Thus, the
lymphocyte count is the major factor in RNA yield, but
accounts for only about 30% of the variability.
Whole blood RNA biomarkers

The RNAseq data was subjected to minimal normalization, using only the raw RPKM data for analysis. When
sequencing was completed, the GRCh37/hg19 assembly
was the most fully annotated in our lab. The RNAseq
reads were aligned, and then parsed and counted
against the 161,038 transcripts in hg19. Transcripts
with very low-level expression were filtered by requiring RPKM > 0.01 in 70% of the samples of at least one
group, which had a minimal impact on the number of
included transcripts (157,943). Dividing the samples by
CAD level ≤ 20% (LOW, n = 48) versus > 20% (MID+,
n = 48) and averaging across patients yielded the geometric mean expression per group per transcript, as shown
in Fig. 2. Remarkably, without any normalization per
sample beyond RPKM, the RNAseq data shows excellent linearity over 23 log2 orders of magnitude, with the
highest level of gene expression observed for hemoglobin
B, at an average of RPKM of ~ 65 K (16 in log2 scale) in
both groups. Compared to typical microarray data, the
RNAseq shows less noticeable increases in variability at
low levels of gene expression, and no detectable saturation of the signal at very high gene expression.
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Table 1 Patient demographics: discovery cohort
Coronary artery stenosis
Low
Mean
N per group

48

Age (years)

57.5

Race (% minority)

62.5

Sex (% male)

45.8

BMI

34.7

MID+
S.E.M

Mean

1.49

62.5

P value*
S.E.M

uncorrected

48
1.41

45.8
56.2
1.32

31.4

0.02*
0.10
0.31

0.97

0.05*

Current smoker (%)

8.3

14.6

0.34

Hypertension (%)

70.8

75.0

0.86

Systolic BP

135.85

3.02

137.05

3.80

0.81

Diastolic BP

72.67

1.66

72.67

1.83

1.00

4.80

167.09

4.91

0.62

Dyslipidemia (%)

58.3

Total Chol. (mg/dL)

180.50

70.8

0.28

LDL Chol. (mg/dL)

109.00

4.49

95.64

4.74

0.61

VLDL Chol. (mg/dL)

13.00

0.61

23.45

1.60

0.23

HDL Chol

51.00

0.61

47.82

1.40

0.67

Tri-glycerides

66.00

3.06

117.45

7.97

0.23

Creatine kinase-(U/L)

152.00

19.60

172.75

19.78

Diabetes (%)

35.4

Aspirin (%)

52.1

PTT (s)

29.77

33.3
62.5
0.60

30.96

0.87
0.83
0.21

0.67

0.19

PT (s)

12.97

0.24

13.13

0.41

0.74

INR

0.99

0.02

0.96

0.01

0.26

WBC (× 103/uL)

6.99

0.35

6.92

0.36

0.89

RBC (× 106/uL)

4.63

0.07

4.37

0.07

0.02*

Hemoglobin (g/dL)

13.19

0.17

13.16

0.24

0.91

Hematocrit (%)

39.79

0.48

39.02

0.62

0.33

MCV (fL)

85.94

0.75

89.01

0.69

0.01*

MCH (pg)

28.45

0.30

30.00

0.26

0.00*

MCHC (g/dL)

33.06

0.17

33.70

0.18

0.02*

RDW (%)

14.16

0.25

13.03

0.27

0.01*

Platelet Count (× 103/uL)

249.81

8.08

228.98

8.84

0.09

MPV (fL)

10.63

0.13

10.57

0.14

0.76

Seg. neutrophils (%)

56.34

1.83

62.30

1.59

0.03*

Lymphocyte %

32.76

1.74

26.21

1.38

0.01*

Eosinophil %

2.34

0.19

2.33

0.26

0.96

Basophil %

0.40

0.07

0.24

0.07

0.17

Abs. seg. neutrophils (× 103/uL)

4.08

0.24

4.53

0.32

0.31

Abs. lymphocytes (× 103/uL)

2.42

0.25

1.72

0.09

0.02*

Abs. eosinophils (× 103/uL)

0.16

0.01

0.16

0.02

0.95

Absolute basophils (× 103/uL)

0.04

0.00

0.03

0.00

0.22
0.15

Auto monocyte %

7.53

0.34

8.35

0.39

Auto monocyte # (× 103/uL)

0.53

0.03

0.56

0.03

0.51

Immature granulocytes %

0.24

0.02

0.25

0.02

0.62

RNA yield (ng/ul) 50 ul total

121.72

11.1113

96.48

7.50

0.07

Yield (ug/2.5 ml tube)

6.09

4.82

Total RNAseq reads

6.08E+07

4,189,732

5.35E+07

3,691,059

0.19

Filtered reads

2.44E+07

1,876,258

2.02E+07

1,522,361

0.09

Aligned reads (informative)

8.75E+06

773,714

6.65E+06

474,229.5

0.02*
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Table 2 Patient demographics: validation cohort
Coronary artery stenosis
Low
Mean

MID+
S.E.M Mean

P value
S.E.M uncorrected

N per group

37

Sex (% male)

62.16%

Age (years)

62.89

Race (% minority)

16.22%

9.30%

Hispanic (%)

5.41%

2.33%

Height (cm)

173.54

2.12

170.39

1.57

0.23

Weight (kg)

96.11

4.69

86.59

3.25

0.09

BMI

32.01

1.57

29.83

1.04

0.24

SBP

124.62

2.58

127.42

3.02

0.49

DBP

70.19

1.67

68.58

1.40

0.46

MAP

88.35

1.67

88.23

1.68

0.96

HR

69.68

1.95

71.00

2.17

0.66

Heart Rate

69.68

1.95

71.00

2.17

0.66

EF %

54.70

1.67

58.16

1.51

0.13

Dyslipidemia

43.24%

65.12%

0.05*

Hypertension

67.57%

67.44%

0.99

Diabetes mellitus

21.62%

23.26%

0.86

Smoking

5.41%

11.63%

0.33

Aspirin

48.65%

76.74%

Creatinine

0.96

0.04

0.98

0.04

0.69

%Stenosis

1.57

0.48

66.79

3.97

RNA yield (ng/ul)

81.36

2.34

84.54

2.15

6.50E − 25*

Total RNA/tube (ng) 7322.59

43
51.16%
1.74

67.61

0.32
1.79

0.06
0.99
0.47

0.01*

0.32

7608.50

Identification of differentially expressed RNA biomarkers
for CAD

The 96 samples in the Discovery cohort were divided into
LOW CAD (< 20% stenosis, N = 48) versus MID + CAD
(> 20% stenosis, N = 48). The transcripts were filtered to
exclude low expression transcripts (< 0.01 RPKM) and
then compared by ANOV (p < 0.001) to identify a small
set of differentially expressed genes (DEGs). This initial
filtering identified 198 transcripts that include the 59
transcripts highlighted in BLACK in Fig. 2 and detailed
in Additional file 2: Table S1.
By filtering the 198 transcripts for those which had
a > 20th percentile absolute level of expression (RPKM
percentile) in both groups, the list was narrowed to 96
transcripts with higher absolute expression. Of those 96
transcripts, 51 showed a greater than 1.4-fold decrease in
the MID + CAD group, which became the parent list for
identifying smaller sets of CAD-related transcripts. This
combined fold-change/t-test strategy has been established in large, multicenter control studies using spiked
samples as a reliable approach to identify true differences
[21].

Fig. 2 Genome-wide transcript profiling by RNAseq. A total of 96
patients with angiographic results were analyzed by RNAseq of
whole blood RNA depleted of ribosomal sequences. The short reads
were aligned to the human transcriptome (hg19) and counted per
transcript. The raw read counts (R) were normalized only by (Per) the
length of the transcript (K) and the total number of reads obtained
per patient in millions (M) to yield RPKM. The RPKM is expressed
on a log2 scale and averaged across all patients in the LOW CAD
group (n = 48, X axis) versus patients in the MID+ CAD group
(n = 48, Y axis). Each point represents one transcript where the RPKM
was > 0.01 RPKM in 70% of samples in at least one group (157,943
transcripts). Black points represent a set of transcripts identified as
differentially expressed between the 2 groups by a statistical analysis
of fold-change and t-test probability (p < 0.001 uncorrected, and fold
change > 1.5) resulting in 59 transcripts (49 unique, non-redundant)

Comparison of TRACs relative to transcripts related
to clinical risk factors

Because CAD has several known risk factors, such as
hypertension, smoking, and dyslipidemia, the relationship of TRACs to these other parameters was determined. While not strictly statistically significant, the
demographic analysis suggested that the LOW CAD
group tended to be younger, heavier, and more female.
For comparison purposes, classifying the 96 patients by
sex (48 M, 48 F) irrespective of CAD status, and using a
combined filter for > threefold change and p < 0.05 (uncorrected), the analysis identified 84 transcripts that were
‘sex-specific’ (Additional file 2: Table S2). This included
transcripts from the X (XIST) and Y chromosomes, and
yielded an PLSD prediction model that was 97% accurate
(100% accurate for males, 95% for females), simply confirming that the RNAseq data can readily detect obvious
biological differences.
Using a similar approach, RNA biomarkers lists were
constructed for age (young < 60 YO), hypertension, dyslipidemia, BMI, smoking, diabetes, and aspirin use.
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While each biomarker list showed interesting changes in
RNA expression levels, there was very minor overlap with
the TRAC list (Fig. 3). Five transcripts (ABCF2, CHST10,
FAM129C, MAST4, TEX41) were sensitive to CAD and
BMI, even though, to minimize confounding, the BMI list
was derived from LOW CAD patients only. SMYD3 was
identified as sensitive to the age of the subject, albeit with
an alternative transcript ID compared to the TRAC list.
However, the direction of the change, whereby SMYD3
increased with age, is opposite to the change expected on
the basis of the age of the patients with CAD, and thus,
age is somewhat offsetting the CAD effect on SMYD3.
Aspirin use was more common in the MID+ group,
but its correlation with TRACs was statistically nonsignificant. Two transcripts were identified that were
both TRACs and aspirin-sensitive: CHST10 (decreased
only at 81 mg/day dose) and NT5C3B (decreased only at
325 mg/day dose). In general, however, there was little to
no evidence that the TRACs are related to other known
clinical correlates of CAD.
Relationship of TRACs to demographic/clinical predictors
of CAD

Further, a statistical covariate analysis was conducted,
observing that within the LOW or MID + groups, the
TRACs were not significantly affected by the clinical
variables. The CAD status was highly significantly related
to TRAC score (p = 7.78E−11), while among the other
risk factors for CAD, only age was a significant factor for
TRAC score (p = 0.012), thus confirming that the TRACs
appear to be largely independent of known risk factors
for CAD in this cohort (Additional file 1: Fig. S2). Exploring the bivariate relationship between age and the TRAC
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score, there is a slightly negative slope of − 1.22 and R
 2 of
0.056 (p = 0.021, n = 96, Additional file 1: Fig. S3). This
impact of age is consistent with the use of age and sex in
other gene expression models of CAD [22].
Relationship of TRACs to analytical variables

In addition to the clinical covariates, the potential contribution of analytical/technical variables was considered.
Two factors were identified that might affect the types of
transcripts: 1) the MID+ patients tended toward lower
RNA yield and 2) fewer informative (non-rRNA) reads
(LOW = 8.7 M reads, MID+ = 6.7 M reads, p = 0.02).
The likely cause of this difference is the observed difference in lymphocyte counts between groups, which is the
primary source of RNA yield (Additional file 1: Fig. S1),
and potentially in read depth. To determine whether read
depth could contribute to the DEGs, the patients with
read depth of < 5 M informative reads (n = 25) were compared to patients with > 5 M reads (n = 71) and analyzed
in a similar manner for DEGs. Not surprisingly, a large
number of differentially expressed transcripts were identified (1008). However, only 8 transcripts from the 198
TRAC list were sensitive to read depth (APOL4, APTX,
C5ORF60, HIF3A, MYO19, NPAS2, RRP12, TMEM67),
and this is somewhat confounded by an increased number of MID+ in the low depth group. Thus, it is unlikely
that read depth explains the observed pattern of expression in the TRACs.
Interpreting the TRAC signature

To understand the TRAC signature, the 198-transcript
list (Additional file 2: Table S1), generated by analysis
of the complete cohort, was subjected to an in-depth

Fig. 3 Relationship between TRACs and transcripts identified for clinical risk factors. To determine whether the TRACs (CAD, LOW vs MID+ High, 198
transcripts) were sensitive to known risk factors for CAD, the 96 patients were separated into new groups based on their current smoking (yielding
381 transcripts), aspirin use (324), dyslipidemia (250), age (41), sex (81), and BMI (198). In the case of age, sex, and BMI (right cluster), only the LOW
CAD patients were analyzed (n = 48) to prevent confounding with CAD
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analysis. A surprising finding was that 195 of 198 transcripts (98.5%) were down-regulated in the MID and
HIGH (MID+) CAD patients, a pattern that rarely
occurs in RNA expression analysis, where there is typically a balance between increased and decreased transcripts. Furthermore, the changes are essentially all of
the same magnitude (mean =  ~1.7 fold). A similar, but
slightly less stringent analysis, using a T-test/fold change
filter between the LOW vs MID+ groups identified 461
transcripts, largely overlapping with the 198-gene list,
but containing some additional markers of interest,
including FLYWCH1, as discussed below (Additional
file 2: Table S3).
Discriminant ability of TRACs for clinical CAD

A partial least squares discriminant (PLSD) model build
on these 198 transcripts was very accurate at discrimination between groups, showing an overall accuracy of
98.9% (100% for LOW, 97.9% for MID+). This remained
fairly robust even with N-fold internal validation, yielding
overall accuracy of 80% (77% for LOW, 83% for MID+).
Using a smaller 96 transcript set, with higher fold change,
did not improve the predictive ability of the PLSD model
built on it, with overall accuracy of 93% (92% for LOW,
94% for MID+), but still produced a quite powerful test,
with fewer transcripts. However, these complex polynomial models are able to fit almost any classification, and
thus, to minimize ‘over-fitting’, a much simpler linear
model was built using predetermined transcripts connected to T cell function.
This smaller linear model employed 7 transcripts based
on known relevance to T cell function (DGKA, DLG1,
ICOSLG, IKZF4/Eos, SMYD3, TCF3, TRIM28) that were
normalized to their average expression level, and then an
average composite score was calculated (Fig. 4, Upper
Right Panel). The composite score of 7 transcripts was
highly significant between groups (p = 6.02 × 10−12), and
a simple linear prediction model yielded a receiver-operator curve (ROC, via JROCFIT [23]) with a C-statistic of
0.873, sensitivity of 77.4%, specificity of 83.7% and overall
accuracy of 80.2%, with a positive predictive value (PPV)
of 85.4% and negative predictive value (NPV) of 75.0%
(Fig. 4, Lower Right Panel). By comparison, a purely
clinical model using 7 predictors had a C-statistic of only
0.636, with 55.6% sensitivity, 53.3% specificity, 54.2%
overall accuracy, 41.7% PPV, and 66.7% NPV (Fig. 4,
Lower Left Panel). A combined clinical (age) and TRAC
model yielded a much stronger C-stat of 0.917.
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Expression changes in relation to GWAS findings

A variety of GWAS studies have been conducted using
various types of atherosclerotic disease or strongly
related risk factors, and approximately 150 loci have
some reported association with CAD. Several of the
TRACs were essentially identical to prior GWAS loci
containing variants associated with cardiovascular or
immune variables (Table 3). For instance, alpha-1-B glycoprotein (A1BG) associates with hepatocyte growth
factor levels in the MESA cohort [24], and with adverse
cardiovascular outcomes during antihypertensive therapy [25]. C6ORF10 associates with susceptibility to
CAD in Chinese Han [26], Cadherin 13 (CDH13) has
SNPs which associate with multiple CAD risks [27, 28],
COMM domain-containing 5 (COMMD5) has been
identified in rodent models as associated with hypertension [29], the fibrillin 3 locus (FBN3) associates with
metabolic syndrome in the Framingham cohort [30], and
the FCH and double SH3 domains 2 (FCHSD2) locus has
been associated with systemic lupus erythematosus (SLE)
[31], an autoimmune disease frequently complicated by
aggressive atherosclerosis. The methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) Rs6922269 SNP
predicts mortality after acute coronary syndrome [32],
and is a known risk loci for CAD [33]. Phospholipase A2
group 10 (PLA2G10) is also a known CAD risk loci in
humans [34] and mice [35]. Psoriasis is a well-established
risk for CAD, and the psoriasis susceptibility 1 candidate
1 (PSORS1C1) gene expression is reduced in the present
CAD cohort, and its locus is associated with psoriasis
[36], rheumatoid arthritis [37], and capillary leak [38],
and was recently associated with cardiometabolic parameters [39]. Serpin peptidase inhibitor D (SERPIND1, heparin cofactor II) levels have been associated with in-stent
restenosis of peripheral arteries [40], and the staining for
SERPIND1 in human coronary lesions was correlated
with the degree of atherosclerosis in the PDAY study
[41]. Notably, Flywich-type zinc finger 1 (FLYWCH1),
was identified by the CARDIOGRAM consortium as a
driver eQTL risk loci for CAD in vascular and adipose
tissues [42]. Thyroid adenoma associated (THADA) was
identified in a functional expression analysis of a human
beta cell line as potentially relevant to type II diabetes
[43]. Thus, GWAS and expression studies suggest that
several of the whole blood mRNA expression changes
correspond with previously published SNPs for CAD, or
CAD risk factors, such as hypertension, SLE, type 2 diabetes, and psoriasis.
Ontology/pathway analysis of TRACs

The 198-gene list was more fully annotated by both
automated and manual literature mining and genome
analysis. Several levels of analysis were employed.
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Fig. 4 Clinical versus RNA predictors of CAD. a Conventional clinical predictors of CAD plotted for each group in the upper panel, showing Age
(decades/10), Sex (%Male), Symptom type (typical/atypical), Diabetes (%), Hypertension (HTN, %), Family History of CAD (%), and current Smoking
(%). A cumulative CAD risk score is calculated for each patient based on the method of Min et al. and divided by 10 for graphic purposes. The
relationship between the cumulative risk score and CAD was calculated by the Receiver Operator Characteristic (ROC) and a confusion matrix to
identify the accuracy of the method (lower left). b The performance of 7 RNA transcripts as their gene symbols (i.e. DGKA, DLG1) expressed as the
RPKM by CAD group. A cumulative score was computed expressing each transcript as a ratio to the mean of its expression in the entire group,
to prevent highly expressed transcripts from being over-represented. For graphic purposes, the TRIM28 and Cumulative scores are /10. In the
lower panel, the relationship between the cumulative TRAC score (constant-TRAC, to create positive ROC) and angiographically-confirmed CAD is
analyzed by ROC similar to the clinical model for the 48 patients in each group

Initially, because the DEGs tended to all be decreased
by a similar magnitude, transcripts were examined to
determine whether they were indicative of a particular
cell type present in blood that might be associated with
CAD. At least 17 of the TRACs were readily associated
with T-cell function (Table 4, upper). Notably, CYTIP
and PLCG1 have known interactions with the T cell
receptor (TCR) signaling [44, 45]. Likewise, DLG1 and
PPARA are well established regulators of T-cell function, and TIA1 is an intracellular antigen which marks
cytotoxic T-cells [46–48].
As shown in the lower half of Table 4, another 10
transcripts suggest that TRACs might be most closely
associated with regulatory T cells (Treg). Several strong
indications are provided by transcripts such as IKAROS

family zinc finger 4 (IKZF4, aka Eos), which is considered a signature transcript for the Treg cell subset [49],
and which is important in controlling Treg transition
into T-helper (Th) cells [50]. IKZF4/Eos is thought to
be a required corepressor for the FoxP3-dependent
gene silencing that is necessary for maintaining the
stable Treg phenotype [51]. Likewise, Set and Mind
domain containing 3 (SMYD3) is also involved in epigenetic control of FoxP3 expression [52]. Further,
TCF3, aka E2A, is a major transcription factor controlling FoxP3 expression [53], and TRIM28 has been
identified as a member of the FoxP3 transcriptional
complex [54]. Given that FoxP3 is considered the hallmark of Treg cells [55], alterations in the expression of
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Table 3 TRACs with known GWAS or expression associations
Gene name p value

Fold

Fold

Expression (RPKM)

HvsL

MvsL

HIGH

uc061drv.1

2.93E−04

uc059ulu.1

5.07E−04 − 1.57↓

1.01↑

uc061wwa.1 6.36E−04 − 1.44↓

uc063nqr.1
uc059xrj.1
uc064rqz.1

3.79E−04

1.29↑

1.45E−04 − 2.97↓

8.12E−04 − 1.46↓

uc060std.1

7.00E−04

uc058fep.1

6.63E−04 − 1.37↓

uc058vgw.1
uc063sgp.1
uc059rbn.1
uc063mxz.1
uc059xcn.1
uc062bvk.1

1.21↑

2.07E−04 − 1.69↓

7.99E−04 − 2.35↓

8.11E−04 − 1.42↓

3.53E−04 − 4.06↓

9.57E−04 − 1.43↓

− 4.97↓

− 2.22↓

− 1.39↓

− 3.35↓

− 8.68↓

− 1.57↓

− 6.37↓

− 1.52↓

− 1.83↓

MID

Symbol

− 1.24 − 3.56 − 1.25 A1BG

− 0.29 − 0.23

0.24

BLCAP

− 5.67 − 7.78 − 6.04 C6orf10

− 2.86 − 4.41 − 1.29 CDH13
− 0.01

0.64

− 0.02 − 0.18

0.43

COMMD5

− 2.71 − 5.66 − 2.99 FBN3

FCHSD2

− 2.04 − 2.15 − 1.28 MMP17

− 6.59↓

− 2.57 − 4.06 − 1.34 MTHFD1L

− 5.22↓

− 3.46 − 3.82 − 1.44 PSORS1C1

− 1.91↓

− 1.59↓

1.87

1.45

2.38

PLA2G10

− 0.58 − 0.73 − 0.06 RFWD3

uc001zwr.5

8.81E−04 − 1.52↓

9.10E−04

− 1.42↓

− 0.80 − 0.69 − 0.19 SERPIND1

uc064wao.1

3.99E−04 − 1.80↓

− 1.66↓

− 1.08 − 0.96 − 0.23 SLC25A25

− 1.14↓

− 0.19

1.02↑

uc063fxo.1

5.55E−04

uc062iym.1

2.16E−04 − 2.20↓

uc061irb.1

1.02↑

5.78E−05 − 2.01↓

1.67↑

− 1.81↓

− 1.74↓

0.59

0.47

1.30

− 0.41

0.56

SLC12A1

alpha-1-B glycoprotein

NM_130786

Bardet–Biedl syndrome 2

NM_031885

Bladder cancer associated protein

NM_001167820

Chromosome 6 open reading frame 10

NM_001286474

Cadherin 13 transcript variant 5

NM_001220491

COMM domain containing 5

NM_001081004

fibrillin 3

NM_032447

FCH and double SH3 domains 2

NM_014824

Matrix metallopeptidase 17

NM_016155

Methylenetetrahydrofolate dehydrogenase 1L NM_001242768
Phospholipase A2, group X

NM_003561

Psoriasis susceptibility 1 candidate 1

NM_014068

Ring finger and WD repeat domain 3

NM_018124

Serpin peptidase inhibitor D, heparin cofactor NM_000185
Solute carrier family 12A1

NM_000338

Solute carrier family 25 A25

NM_052901
NM_001303250

0.44

SLC25A46

Solute carrier family 25 member 46

0.95

SLC6A20

Solute carrier family 6 (proline transport)

NM_022405

− 1.11 − 0.91 − 0.10 THADA

Thyroid adenoma associated

NR_073394

− 0.91 − 1.07 − 0.38 ZGPAT

Zinc finger, CCCH-type with G patch domain

0.76

uc060vxm.1 4.76E−06 − 3.08↓ − 10.76↓ − 2.48 − 4.28 − 0.86 TMEM161A TRANSMEMBRANE protein 161A

uc061you.1

1.46E−04 − 1.45↓

− 1.61↓

RefSeq

LOW

− 0.71 − 1.21 − 0.06 BBS2

0.09

Description

these transcripts suggest that changes in the abundance
of the Treg population may contribute to the TRAC
signature.
Cell type‑specific RNA markers in relation to CAD level

To explore a potential cell type hypothesis more directly,
published microarray analysis of purified human blood
subsets have identified cell type-specific mRNAs [56],
which were cross-referenced to the current RNAseq transcriptome, and used to build a composite index of ~ 15 to
20 mRNAs relatively unique to each subtype. As shown in
Fig. 5, a composite index of RNA expression levels shows
a trend toward lower expression of lymphocyte markers
in patients with MID to HIGH CAD. This trend is maintained in T-cells, and specifically in CD8 + T-cells, but is
not observed in B-cell or granulocyte-related transcripts.
TRACs do not appear to be markers of circulating
progenitor cells

There is a substantial literature [57], summarized in
Additional file 2: Table S4, that consistently reports
reductions in circulating progenitor cell (CPC) populations in patients with stable CAD [58, 59], or preclinical
atherosclerosis [60]. The major cardiovascular risk factors
are associated with reduced numbers and activity of CPC

NM_001256766
NM_181485

[61]. Conversely, circulating endothelial progenitor cells
(EPC) are increased in acute MI cases [62]. However, it is
unlikely that a decrease in EPC numbers, which are rare
(< 1%), could cause the substantial shift in RNA levels,
detected in whole blood. Nonetheless, the RNAseq data
was analyzed for changes in recognized markers of EPC
and CPC, such as CD34, cKit, PROM1/AC133, and KDR,
and the RNA levels are shown in Additional file 1: Fig. S4.
There was no systematic change detectable: CD34 and
cKit were slightly elevated in MID + CAD, while KDR
and AC133 were decreased by comparable amounts.
The expression of consensus Treg markers by CAD level

A second potential explanation for TRACs as markers of a specific cell type is that there are known reductions in the Treg subset of lymphocytes in atherosclerosis
[63]. An extensive literature documents reduced Treg
abundance, and a relative imbalance in Treg vs T effector (Teff ) cells in patients with CAD (summarized in
Additional file 2: Table S5) [63, 64]. To test for the potential changes in Treg, the mRNA levels of known Treg
markers was analyzed in the CAD groups. As shown in
Fig. 6, five established markers of Treg cells, FoxP3, CD4,
CD25, ETS1, and RUNX1, showed a stepwise decrease in
mRNA expression from LOW, MID, to HIGH CAD. By
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Table 4 TRACs related to T cell and Treg function
Gene name

p value

Fold HvsL

Symbol

Description

RefSeq

Related to T cell function
uc064mjf.1

8.03E−04

uc061mig.1

6.28E−04

uc061otq.1

1.03E−04

uc058pdy.1

7.75E−04

uc062seb.1

9.10E−04

uc057gll.1

5.73E−04

uc063okh.1

1.65E−04

uc062dbe.1

3.38E−04

uc059uvj.1

5.04E−04

uc062xlo.1

2.87E−04

uc057jvt.1

6.40E−04

uc061xai.1

5.74E−04

uc062fel.1

1.70E−04

uc058jqr.1

9.54E−04

uc064bpk.1

5.85E−04

uc061kij.1

8.52E−04

Relevant to Treg and/or FoxP3
uc063bvz.1

9.62E−05

uc058uor.1

8.95E−04

uc061yty.1

1.48E−04

uc058pgk.1

8.59E−04

uc063ljh.1

9.84E−04

uc063ady.1

5.93E−04

uc057qye.1

2.67E−04

uc057jcy.1

5.62E−04

uc061duf.1

4.36E−04

uc060rek.1

4.39E−04

− 1.24↓

− 1.21↓

− 1.47↓

− 1.36↓

− 1.18↓

− 1.73↓
1.12↑

− 1.56↓

AP3M2

adaptor-related Protein 3, mu 2

NM_006803

CHST10

Carbohydrate sulfotransferase 10

NM_004854

CYTIP

Cytohesin 1 interacting protein

NM_004288

DGKA

Diacylglycerol kinase, alpha

NM_201554

DLG1

DISCS, large homolog 1

NM_001204386

EPS15

EGF receptor pathway substrate 15

NM_001981

FOXP4-AS1

FOXP4 antisense RNA 1

NR_126417

GATSL3

GATS protein-like 3

NM_001037666

1.44↑

GPR56

Adhesion G prot-coupled recep G1

NM_001145774

− 1.15↓

NUP54

Nucleoporin 54 kDa

NR_103781

− 1.51↓

− 1.75↓

− 1.09↓

− 1.26↓

− 1.30↓

− 1.45↓
− 1.25↓

− 1.38↓

− 1.62↓

− 3.36↓

− 1.59↓

− 1.34↓

− 1.35↓

− 1.55↓

− 1.33↓

− 1.39↓

PHGDH

Phosphoglycerate dehydrogenase

NM_006623

PLCG1

Phospholipase C, gamma 1

NM_182811

PPARA

perox. prolif. activated rec. a

NM_001001928

RAD52

RAD52 homolog

NM_001297421

SCIN

Scinderin

NM_033128

TIA1

Cytotoxic granule-assoc. RNA BP

NM_022173

AHRR

Aryl-hydrocarbon rec. repressor

NM_001242412

HIP1R

Huntingtin interact. prot.1 related

NM_003959

ICOSLG

Inducible T-cell costimulator ligand

NM_001283052

IKZF4

IKAROS family zinc finger 4 (Eos)

NM_022465

IRF4

Interferon regulatory factor 4

NM_001195286

LRBA

LPS-responsive, beach anchor

NM_006726

SMYD3

SET and MYND domain containing 3

NM_022743

STRIP1

Striatin interacting protein 1

NM_001270768

TRIM28

Tripartite motif containing 28

NM_005762

TCF3

Transcription factor 3

NM_003200

comparison, the expression of an irrelevant marker, such
as the prostaglandin E receptor 3 (PTGER3), does not
show this CAD-related trend.
TRACs correlate with FoxP3 and other Treg markers

To further understand whether the TRACs are related
to Treg cell changes, the expression levels of FoxP3 were
correlated with 24 other known Treg markers or TRACs
across all 96 patients (Additional file 2: Table S6). The
strongest correlations of FoxP3 occurred with AHRR
(0.72, TRAC), CD8A (0.53), PDCD1 (0.48), ICOSLG
(0.41, TRAC), RUNX1 (0.36), and PSORS1C1 (0.35,
TRAC) (all p < 0.001), while other known Treg markers,
such as IKZF4/Eos (0.13, p > 0.2, TRAC), showed weaker
correlations. For reference, 2 splice variants of ICOS are
correlated at 0.87, and 2 variants of B3GAT1 are correlated at 0.64. Furthermore, the levels of ICOS and ICOSLG mRNA in whole blood are reduced comparably to
FoxP3 in both the MID and HIGH CAD groups (Additional file 1: Fig. S5). Thus, the expression of several of

the TRACs (AHRR, ICOSLG, PSORS1C1), correlate with
FoxP3 RNA levels in these patients to a degree similar
to or better than other known Treg markers (RUNX1,
IKZF4/Eos).
Treg/Teff cell ratio relative to TRAC RNA expression

To determine whether a reduction in Treg cell counts
in blood would be sufficient in magnitude to produce
the observed changes in RNA levels, 8 publications
that reported Treg percentages in normal and CAD
patients, such as unstable angina or acute coronary syndrome (ACS), were reviewed, and the change in Treg
percentage was computed (Additional file 2: Table S5).
The average Treg abundance, typically defined as
CD4+CD25+CD127low by flow cytometry, was 4.7% in
normal, but decreased to 3.2% in CAD or unstable angina
(30.3% reduction). This reduction in Treg abundance
would translate to a 1.43-fold difference in Treg RNA
levels, assuming that these markers are relatively unique
to Tregs. Thus, the 1.47-fold reduction in mRNA for the
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consensus FoxP3 marker, and the ~ 1.7-fold reduction in
the TRACs, is quite consistent with the reported reduction in Treg cell numbers in CAD.
TRACs and Treg markers are sensitive to RNA stabilization
procedures

Fig. 5 Expression of cell-type specific transcripts as a function of CAD
status. Transcripts with relative specificity toward particular blood
cell subsets was curated from published studies. The expression
level (RPKM) of those transcripts (10–15 per cell type) in the RNAseq
data was calculated and averaged for each cell type. The average
expression was calculated for patients in 3 groups of CAD severity,
LOW (n = 48), MID (n = 28), or HIGH (n = 20)

Given that the Treg imbalance data has been reported
from multiple labs worldwide, it is curious that changes
in established Treg markers have not been reported in
any prior publications using expression profiling of blood
from patients with stable CAD. One possible explanation
is that RNAseq is potentially much more sensitive than
microarray methods, allowing these low abundance messages to be detected more accurately. A second consideration is that, to our knowledge, all prior CAD microarray
studies were conducted using RNA stabilized and isolated from Paxgene preservative tubes, while the present
studies employed Tempus preservative tubes. In the current studies, Tempus tubes were selected due to studies in
our lab, and others, showing a ~ 10 to 20% better yield of
RNA at 20% lower cost and 40% less time [65, 66]. Based
on prior studies demonstrating quite marked changes in
gene expression profiles based on the RNA stabilizer [20,
65, 66], the effect of the RNA stabilizer was examined
for its impact on TRACs versus neutrophil transcripts
(DEFA3) and other selected markers (IL12A, SELL,

Fig. 6 RNA levels of markers for Treg cells as a function of CAD level. The expression levels ( log2 RPKM) of 5 known Treg markers (FoxP3, CD4, CD25,
ETS1, Runx1) and 1 control (PTGER3) is plotted for 3 groups of patients with LOW (≤ 20% stenosis, n = 48), MID (21–69% stenosis, n = 28), or high
CAD (≥ 70% stenosis, n = 20). Points are mean per group with bars ± s.e.m

McCaffrey et al. BMC Med Genomics

(2021) 14:216

SOD2, TBA1, ACTB). As shown in Additional file 1:
Fig. S6, blood from the same normal subjects at the same
time, but collected into two different collection/stabilizer
tubes, showed marked differences in the levels of mRNAs
measured by droplet digital PCR (ddPCR). Several of the
TRACs, such DGKA, DLG1, ICOSLG, and TCF3, were
detected ~ 4 to sixfold more efficiently in blood RNA isolated from Tempus versus Paxgene tubes. Chemically,
the Paxgene tubes are based on a cationic detergent that
creates micellar-like structures that protect RNA, while
Tempus uses the strong chaotrophic effects of guanidinebased salts to denature RNAses and dissolve RNA/protein complexes. Thus, the Tempus/chaotrophic approach
appears to isolate Treg-related mRNAs better than the
Paxgene/detergent approach.
Analysis of TRACs in an independent validation cohort
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patient to patient level, which could reflect the different
demographics of the 2 groups.
Identification of TRACs shared by the discovery
and validation cohorts

Using the strictest filtering, exactly as applied to the
Discovery set to obtain the 27 g predictors used above,
the Validation dataset yielded 22 transcripts, but none
were identical matches at the gene symbol level between
cohorts. By relaxing the filtering criteria to create DEGs
of about 350 unique and annotated transcripts in each
cohort (p < 0.01, fc1.2), 16 exact matches were observed,
which is 4.5 times greater than expected by chance
(p < 8.7 × 10−7) (Additional file 2: Table S7). An additional
17 close matches were observed (ie. ELP3 vs ELP2), and
37 more matches that were close or identical to HG19
alignments of the Discovery cohort, for a total of 70
close or exact matches. Both the Discovery and Validation DEGs (92% decreased in CAD) shared a strong trend
toward decreasing expression in the CAD group.

Simple linear classification models built in the Discovery cohort (Fig. 4) and then applied to the RNAseq values obtained from 80 patients in the Validation Cohort
did not perform much better than random in the validation set. However, it was quickly noted that the Discovery
RNAseq had been aligned to the GRCh37/hg19 human
genome, while the Validation set, aligned at a later date,
used the GRCh38/hg38 reference genome. Thus, the
entire Discovery RNAseq database was realigned to the
hg38 genome and then reanalyzed for DEGs to build a
classification model. As a quick test of the stability of a
predictive model, in the hg38-aligned Discovery dataset,
strict filtering for > twofold change at p < 0.001 identified 27 transcripts of which 23 (85%) were expressed at
a lower level in the CAD group. A PLSD model built on
those 27 transcripts was 95.5% accurate in LOW, 91.9%
accurate in MID+, for 93.3% overall accuracy. However,
those same transcripts were less predictive in the Validation dataset, but still informative, showing 78.4% accuracy for low, 62.8% for MID+, with 70% overall accuracy.
Thus, the hg19 vs hg38 alignments play a significant role
in the stability of the TRAC signal, but the discriminant ability of PLSD models remains imperfect between
cohorts. To understand this discrepancy, the DEGs identified by each cohort were analyzed.

These transcripts common to both datasets were used to
determine if any enrichment of a particular cell type was
evident by comparing them to the precurated Blood Atlas
RNAseq database. The results indicated the greatest similarity to T cells, with 12 exact or close matches (4.3-fold
over-representation, p = 9.8 × 10−6, Fisher Exact test).
Rather striking in this group of T cell-related transcripts,
identified as significantly decreased in both cohorts, is
FoxP1. While FoxP3 is considered a pivotal transcript in
Treg development, FoxP1 is likewise a well-known and
critical determinant of Treg maturation [67].
By comparison, the overlap of the shared DEG list
with other cell types is less striking: B cell (1 exact, 4
close matches, 3.5 fold enrichment, p < 0.014), granulocytes (1 exact, 5 close matches), monocyte/macrophage
(1 exact, 4 close matches), natural killer (NK) cells (1
close match), dendritic cells (3 exact, 4 close matches).
Some transcripts, especially OSBPL10, were found as an
exact match on multiple cell types, and thus do not truly
inform the cell type analysis.

Correlation between Discovery and Validation expression
levels for TRACs

Prevalence of transcripts associated with stress granules
(SG)

Using the list of 599 DEG transcripts identified in the
Validation set, it was determined that their expression levels in the Discovery set were highly correlated
for both the low (r = 0.96), and Mid + (r = 0.98) CAD
groups. Thus, quantitation of the transcript levels in the 2
cohorts was very similar, at least at the group level (LOW
vs MID +). Thus, the variation in the DEGs between the
2 cohorts is more likely attributable to variation at the

In addition to the apparent similarity of TRACs with
Treg markers, it was also noted that a disproportionate number of transcripts had a known association with
stress granules (Additional file 2: Table S8). Stress granules are membrane-less granules that result from liquid
to gel transitions under cellular stress, and contain RNAs
that are being sequestered from translation during various stressors, such as nutrient stress. Fortunately, other
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groups have used relatively unbiased approaches, such
as microarrays and RNAseq, to identify RNA transcripts
retained in SG during stress [68]. Thus, this hypothesis
was tested more formally by comparing the TRACs to
known SG transcripts and determining whether the overlap was greater than expected by chance.
In the initial hg19 TRAC list (198 transcripts, Additional file 2: Table S1) there was noticeable similarity to previously published lists of SG transcripts [68].
For instance, of the 198 TRACs, 34 were near or exact
matches to known SG transcripts, reflecting a fivefold
overrepresentation (p = 9.5 × 10−15). This association
held strong when the TRACs common to both studies
were analyzed for their similarity to a previously curated
list of 723 known SG transcripts, whereby there was a
25-fold enrichment for SG transcripts (p = 4.04 × 10−39).
A summary of these transcripts is shown in Additional
file 2: Table S8, and 10 transcripts are depicted graphically in Fig. 7.
The stress granule-related RNAs include dead box proteins (DDXs, including DDX46, DDX51, DDX54), which
are a family of RNA helicases that regulate RNA biogenesis, editing, folding, translation, and decay, as well as
having critical antiviral activities [69]. Likewise, EDC3
is considered an important regulator of mRNA translation and decay [70], and interestingly, DDX proteins
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(i.e. DDX6) are known partners to EDC3 and mRNA
decapping enzymes in the regulation of P-body assembly and function [71]. Of note is the Lamin A (LMNA)
transcript, which is the target of germline mosaic mutations in Hutchinson-Guilford Progeria, a premature
aging syndrome characterized by aggressive atherosclerosis and myocardial infarction in adolescents [72]. Also
of interest, special AT-rich binding protein (SATB1) is a
key chromatin protein that is a well-established modulator of T cell progenitor maturation [73]. Notably, SATB1,
along with IKZF4/Eos, IRF4, and GATA1, are considered
a Treg ‘locking’ genes [74].
Potential involvement of cilia/immune synapse transcripts

During manual curation of the DEG transcripts from
both cohorts, there was an apparent overrepresentation
of transcripts related to cilia, synapses, and adhesion:
functions not normally associated with circulating cells.
A representative list of 11 such transcripts derived from
the DEGs common to both cohorts is shown in Additional file 2: Table S9. An excellent example is BardetBiedl Syndrome 2 (BBS2) which is a heritable cause of an
autosomal recessive syndrome characterized by central
obesity, rod-cone dystrophy, renal and vascular abnormalities that emanate from a central defect in cilia assembly and synaptic function [75]. Related transcripts that
appeared in only one of the cohorts includes dystonin
(DST), which likewise affects the ciliary connections in
the ear, causing congenital deafness, but has also been
associated by GWAS with CAD [76]. Other DEGs common to both cohorts include copine 3 or 6 (CPNE3/6)
which are components of the ciliary body, and affects
neural plasticity, but coincidentally, reduced CPNE3
expression is associated with the risk of acute MI and
stable CAD [77]. A potential connection between these
cilia/synaptic transcripts and the Treg changes in atherosclerosis is that the maturation of Tregs likely depends
on proper immune synapse formation in maturing T cells
[78].
Comparison of TRACs to prior microarray‑based biomarker
panels

Fig. 7 Schematic representation of stress granule-regulated
transcripts. Analysis of the transcripts associated with CAD (TRACs)
indicated an apparent enrichment for transcripts previously known
to be associated with stress granules, which are membrane-less
aggregates of proteins and RNA formed when cells are exposed to
a variety of stressors, listed on the left. Under stress, these TRACs, of
which 10 are shown here (DDX, EDC3, etc.), translocate from active,
translatable forms in the cytosolic machinery, to sequestered, inactive
forms in the stress granule. Molecular images courtesy of www.somer
sault1824.com under a Creative Commons license

Other published works have identified transcripts with
predictive value for CAD based on Affymetrix array
technology and PaxGene blood RNA preservation tubes
[12]. For comparison purposes, these published transcripts were matched by gene symbol to RNAseq transcripts, identifying 17 transcripts in the current RNAseq
dataset. The expression levels of these array-based markers were overall much higher than TRACs, but surprisingly, the RNA levels did not differ between LOW and
MID + (average log2 RPKM = 3.26 vs 3.31, p = 0.94)
(Additional file 2: Table S10). These 17 transcripts were
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used to build a classification model that yielded only
36.7% accuracy (LOW 45.1%, MID 10%, CAD 37.5%, w/
33% = random). However, in fairness to the prior CAD
biomarkers, it is difficult to extrapolate their weighting
algorithm to the RNAseq data, and that might improve
the prediction model.

Discussion
The analysis of the RNA transcriptome in relation to
angiographically confirmed CAD offers several major
advantages in both our basic science understanding of
CAD and in clinical medicine. First, if blood biomarkers
can be identified, it might be possible to reduce invasive
testing, such as cardiac catheterization, as well as more
judiciously use imaging resources, such as CT and MR
angiography. Secondly, it would be possible to improve
diagnosis of CAD in rural areas worldwide, where invasive or advanced imaging methods are unavailable.
Finally, the proposed biomarkers potentially can serve
both as therapeutic targets and markers to monitor the
appropriateness and efficacy of new or existing therapies, such as statins or PCSK9 inhibitors. For instance,
Treg numbers have been shown to be responsive to statin therapy, and so it might be possible to use TRACs to
monitor statin therapies.
The connection between the immune system and
atherosclerosis is extensively documented. Blood components, especially monocytes/macrophages [79], neutrophils, lymphocytes [80], and platelets mechanistically
contribute to the development of CAD [81]. Recently,
the microanatomy of the human carotid atherosclerotic
lesion has been analyzed by single-cell transcriptomics,
revealing at least 14 subtypes of cells, including several
T cell subsets [82]. The present results are consistent
with the extensive evidence that CAD is associated with
changes in the Treg/Teff ratio, lipid imbalances, inflammation, microbiome changes, and autoimmunity in atherosclerosis [83]. There is a large and fairly consistent
literature demonstrating changes in the Treg/Teff ratio
in patients with CAD [84–88], and the observed cellular
changes would be consistent in both direction and magnitude with the detected changes in mRNA expression
in the present studies (Additional file 2: Table S5). One
interpretation of the beneficial effects of statins is that in
addition to lowering LDL cholesterol, statins can induce
FoxP3 + Treg cells, via modulation of TGF-ß signaling
[89, 90]. Beyond the reproducible clinical correlations,
experimental manipulation of Treg levels in mouse models of atherosclerosis suggests a potentially causal relationship [91]. Furthermore, it has been suggested that a
Treg-oriented immunomodulatory approach may offer
therapeutic potential for atherosclerosis [92, 93].
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The relationship between Treg dysfunction and atherosclerosis is further observed through the well-known
incidence of atherosclerosis in various autoimmune diseases, most notably in the case of systemic lupus erythematosus (SLE) [94]. While the relationship between
Tregs and SLE is complex, there is a general consensus
that deficient Treg activity is one element of SLE [95],
and thus, might also be a component of SLE-associated
atherosclerosis [96]. Likewise, psoriasis and psoriatic
arthritis, which are associated with Treg imbalances,
have well-established associations with atherosclerosis [97–99]. The immune-CAD connection is seen quite
clearly by an apparently causal relationship in immunemediated transplant arteriosclerosis [100]. Further evidence for the immune-CAD connection derives from the
proven efficacy of rapamycin and related compounds,
which are antibiotics/immunosuppressants, to block coronary artery restenosis. Rapamycin is known to increase
Treg numbers and function at clinically relevant levels
[101]. Recent findings provide fairly direct evidence that
the cytokine responsiveness of T cell subsets is a better predictor of CAD than CRP [102]. Important recent
studies indicate that Tregs license the pro-resolving abilities of plaque-resident macrophages in order to facilitate
plaque regression [103].
Many of the TRACs identified herein have known relationships with Treg function, as shown schematically in
Fig. 8. Foremost, the FoxP3 transcription factor is considered the definitive marker for the Treg subset and is

Fig. 8 Schematic representation of Treg-related TRACs identified by
RNAseq. The control of FoxP3 mRNA and protein expression is known
to be controlled by many factors, including promoter methylation, as
well as transcriptional regulation by SMYD3, TCF3/E2A, and IKZF4/Eos.
FoxP3, in turn, is itself a transcriptional regulator, in association with
cofactors such as TRIM28, IRF4, and others. The FoxP3-sensitive target
genes, and other regulators such as AHRR, ICOS, TGF-ß, and mTOR, are
then intrinsic components of the transition of Treg progenitor cells to
functional Tregs. Molecular images courtesy of www.somersault1824.
com under a Creative Commons license
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thought to transcriptionally regulate a set of transcripts
involved in Treg function. FoxP3 is itself epigenetically
controlled by promoter demethylation and transcription
factors, such as SMYD3, IKZF4/Eos, and TCF3/E2A, to
allow stable expression in Tregs. Once transcribed and
translated, FoxP3 regulates Treg-specific transcription
via known promoter binding sites [55] and by interaction
with a number of co-regulators, including RUNX1 [104],
TRIM28, and IRF4 [105], which, along with SMYD3,
IKZF4/Eos and TCF3, were identified as TRACs in the
present studies. Other studies indicate that two isoforms
of diacylglyceral kinase (DGKA, DGKZ) have been implicated in T-cell anergy [106], and DGKZ has been implicated in the generation of natural Tregs via modulation of
the NFkB signaling through c-rel [107].
The ICOS/ICOSLG system is potentially important
because athero-prone LDLR(-) mice transplanted with
ICOS-deficient marrow develop more severe atherosclerosis [108]. Treg can be either ICOS+ or ICOS− [109],
and typically ICOSLG is considered as a marker of a dendritic cell or innate lymphoid cell type 2 (ILC2), whereby
ICOS on the Treg would engage ICOSLG on the ILC2s
[110]. Flow cytometry analysis of Tregs in MI patients
showed a subset of ICOS+ type to be preferentially
affected [111]. Thus, the decrease in ICOSLG suggests
that there may be some type of coordinate decrease in
both Treg and ILC2 numbers or function.
The current studies differ from prior microarray-based
analysis of CAD in several important ways. The current
studies used a broader definition of CAD that would
include earlier and more diffuse, but less occlusive disease. This definition also provided a better balance
between the sizes of affected and unaffected groups. Further, prior studies used Paxgene blood RNA preservative,
which is known to produce a very different RNA profile,
while the present Tempus system was more sensitive for
Treg markers. Likewise, RNAseq appears to be important for detecting changes in Treg activity and provides
numerous quantitative and qualitative advantages over
microarrays.
There are certain limitations in the present studies.
First, the TRAC signature could be related to unidentified risk factors or drug treatments that differ between
groups. While it is difficult to completely rule it out,
based on the collected variables, we cannot identify a
clinical covariate that would differ sufficiently to create
this effect. Second, it is possible that the TRACs would
detect disease in arteries other than the coronaries, but
this would still have tremendous diagnostic value. A third
limitation is that the clinical endpoint of an invasive coronary angiography (ICA) is excellent, but still imperfect
at detecting coronary disease. Up to 75% of symptomatic
patients that appear to have normal arteries by ICA can
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be shown by CT angiography to have significant atherosclerosis that does not occlude the artery [112]. The
TRAC test would likely report these patients as positive,
while they would be scored as angiographically negative
for CAD by ICA. Future validation studies will need to
incorporate CT angiography as an additional endpoint
to avoid these ambiguous ‘false positives’ on blood-based
tests. Likewise, TRAC-positive patients that are angiographically negative, could be in the early stages of the
disease process, but that could be addressed only by a
long-term follow-up study.
The present studies suggest several important directions for future investigation. Bioinformatically, it would
be valuable to analyze the co-expression network of the
transcripts, and analyze any RNA editing, differential
splicing, and allele usage that might be occurring in CAD.
The identification of RNA biomarkers that are associated
with CAD has the potential to help dissect the mechanisms of atherosclerotic initiation and progression. It is
likely worthwhile to further investigate the regulation of
these transcripts by stress granules, as one component
of immune dysfunction in coronary disease. Further, a
potential connection between stress and the function
of the immune synapse could elucidate specific mechanisms of disease, and targets for therapy, or prevention.
Through high-throughput screening, dozens of FDAapproved compounds that stimulate Treg generation
have already been identified [113]. Further refinement in
the quantitation of these RNA biomarkers could lead to
blood-based diagnostics for CAD, that would be a valuable addition to the diagnostic toolkit.
A long-term goal is to identify TRACs that may be predictive of CAD in asymptomatic, but ‘at risk’ individuals,
especially middle age patients with one or more known
risk factors [114]. Of the more than a million heart
attacks per year in the US, approximately 50% of cases
had no overt warning signs, and 50% of first heart attacks
are fatal. Thus, an ‘early warning sign’ from blood-based
RNA profiling could allow the patient to be referred for
minimally-invasive diagnostics, such as stress tests, CT
calcium scores, or MR/CT angiography, and thus hopefully reducing the incidence of heart attacks and strokes.

Conclusions
Transcriptome-wide profiling of whole blood RNA
from patients with CAD identifies a pattern of changes
that parallels known defects in the number and function of the regulatory T cell subset. The RNA pattern
defines a risk that is independent of other known clinical risks, and thus could add value to future risk stratification models. Simple linear classification models using
only seven transcripts provides surprisingly strong
prediction of CAD status as determined by invasive
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coronary angiography. The RNA changes are consistent with stress-related changes in the immune synapse,
which may help to define the precise cellular mechanisms of atherosclerotic lesion formation.
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